Johnson & Johnson - JNJ STOCK NEWS

Johnson & Johnson (NYSE: JNJ) announced on April 20, 2021, that the European Medicines Agency's Pharmacovigilance Risk Assessment Committee confirmed the positive benefit-risk profile of its COVID-19 vaccine. Following the review of rare adverse events, the company will update vaccine information to include guidance on diagnosing and managing these cases. Shipments of the Janssen COVID-19 vaccine will resume in the EU, Norway, and Iceland. The vaccine demonstrated 85% effectiveness in preventing severe disease during the ENSEMBLE Phase 3 trial, with continued monitoring by health authorities.

Johnson & Johnson (NYSE: JNJ) reported strong first-quarter 2021 results, with reported sales reaching $22.32 billion, representing a 7.9% increase from $20.69 billion in 2020. Net earnings rose to $6.20 billion, up 6.9% year-over-year, resulting in an EPS of $2.32. The Pharmaceutical segment led growth with a 9.6% increase, driven by key products like DARZALEX and STELARA. Medical Devices also saw an 8.8% growth, aided by recovery from COVID impacts. However, Consumer Health segment sales declined 2.3% due to prior year comparisons.

Johnson & Johnson (NYSE: JNJ) has announced a 5.0% increase in its quarterly dividend, raising it from $1.01 to $1.06 per share. This marks the 59th consecutive year of dividend increases, reflecting the company's strong financial position and confidence in future growth. The annualized dividend is now $4.24 per share, up from $4.04. The next dividend is payable on June 8, 2021, to shareholders recorded by May 25, 2021, with an ex-dividend date of May 24, 2021.

Johnson & Johnson (NYSE: JNJ) has signed an agreement with the African Vaccine Acquisition Trust (AVAT) to supply up to 400 million doses of its single-shot COVID-19 vaccine to African Union member states. Initial deliveries are set for Q3 2021, pending regulatory approvals. The vaccine has shown a 67% reduction in symptomatic COVID-19 and is 85% effective at preventing severe disease. J&J's vaccine is designed for wide distribution, remaining stable at common refrigeration temperatures, enhancing its accessibility in remote areas.

Johnson & Johnson (NYSE: JNJ) announced that the World Health Organization (WHO) granted Emergency Use Listing (EUL) for its single-shot COVID-19 vaccine. The vaccine shows a 67% reduction in symptomatic COVID-19 and 85% effectiveness against severe cases. This approval is pivotal for global vaccine distribution, particularly through the COVAX Facility, aiming to provide equitable access to lower-income countries. The vaccine's compatibility with standard storage and distribution makes it significant for pandemic response. Previous authorizations include Emergency Use Authorization in the U.S. and conditional approval in the EU.

Johnson & Johnson (NYSE: JNJ) announced that the CDC's Advisory Committee on Immunization Practices has recommended its single-shot COVID-19 vaccine for individuals 18 and older under Emergency Use Authorization (EUA) granted by the FDA. The vaccine, developed by Janssen, aims to enhance the U.S. national immunization program. Johnson & Johnson plans to deliver 100 million doses in the first half of 2021 and will file for a Biologics License Application later this year. The company is committed to making the vaccine available on a not-for-profit basis during the pandemic.

On February 27, 2021, Johnson & Johnson (NYSE: JNJ) announced that the FDA issued Emergency Use Authorization for its single-dose COVID-19 vaccine. The decision is based on Phase 3 ENSEMBLE study data showing 85% effectiveness in preventing severe disease. The company aims to deliver 100 million doses in the U.S. by mid-2021. The vaccine, which has not yet received full FDA approval, utilizes the AdVac® vaccine platform and presents advantages in storage and distribution, aiding in global vaccination efforts.

On Feb. 26, 2021, Johnson & Johnson (NYSE: JNJ) announced that the FDA's VRBPAC recommended Emergency Use Authorization for its single-shot COVID-19 vaccine for adults. The recommendation was based on the Phase 3 ENSEMBLE trial demonstrating safety and efficacy. If authorized, 20 million doses will be available by March, with a goal of 100 million by mid-2021. The vaccine can be stored at standard temperatures, enhancing distribution. The company is also pursuing approvals in Europe and other global markets to combat COVID-19.

On February 19, 2021, Johnson & Johnson announced that Janssen-Cilag International submitted an Emergency Use Listing for its single-dose COVID-19 vaccine candidate to the WHO. This submission follows the completion of the rolling data submission process, which includes interim results from the Phase 3 ENSEMBLE trial. The vaccine aims for equitable access, especially for lower-income countries, with plans to deliver up to 500 million doses via the COVAX Facility through Gavi. The Company is dedicated to global access on a not-for-profit basis during the pandemic.